Answers are grounded in this paper and cite their sources.
Analysis shows cost-effective prevention of RSV in patients with COPD, indicating significant health benefits.
These results indicated that a single dose of adjuvanted RSVPreF3 vaccine in patients with COPD aged 60-74 years in Italy is a cost-effective preventive option that could potentially reduce RSV-related disease burden and costs over five years.
No takes yet. Share an insight, caveat, or question.
Puggina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: